Account
Articles
05.03.2017
Managed entry agreements

MEAs are also known by other names such as risk-sharing agreements, value-added services, and result...

Read more
Articles
05.01.2017
How NICE is coping with managing the CDF

This process aims to be completely transparent , to enable faster patient access to oncology treatme...

Read more
Articles
21.11.2016
Potential changes to NICE

NICE has recently published a consultation on changes to its appraisal process to "fast track" some ...

Read more
Articles
14.11.2016
Early scientific advice procedures in the EU

This analysis compares the different methods of seeking payer scientific advice, including EMA joint...

Read more
Articles
13.10.2016
German pricing and market access laws

The German Ministry of Health has recently published its final bill concerning pricing and market ac...

Read more
Articles
05.10.2016
Challenges for biosimilar market access

Biosimilars have the potential to be considered comparable to generics and offer healthcare benefits...

Read more
Articles
20.09.2016
Maximising international reference pricing

International Reference Pricing (IRP) is a means to control national prices by using prices in other...

Read more
Articles
05.09.2016
Increased HTA harmonisation in the EU

The latest policy document for the European Commission outlines multiple scenarios for HTA harmonisa...

Read more
Articles
25.06.2016
German pricing and market access law changes 2017

The German Ministry of Health has recently published its final bill concerning changes to the market...

Read more
Articles
15.06.2016
The challenge in securing patient access

Enabling physicians to identify patients who are most likely to respond to treatment thereby achievi...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.